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Regulatory mechanisms leading to 
differential Acyl-CoA synthetase 4 
expression in breast cancer cells
Melina A. Dattilo, Yanina Benzo, Lucía M. Herrera, Jesica G. prada, Ana F. Castillo, 
Ulises D. orlando, Ernesto J. podesta & Paula M. Maloberti
Acyl-CoA synthetase 4 (ACSL4) overexpression plays a causal role in the aggressiveness of triple 
negative breast cancer. In turn, a negative correlation has been established between ACSL4 and 
estrogen receptor alpha (ERα) expression. However, the upstream regulatory mechanisms leading to 
differential ACSL4 expression between triple negative breast cancer and ERα-positive cells remained 
unknown. We performed the characterization of the human ACSL4 promoter and the identification 
of transcription factors involved. Deletional analysis demonstrated the proximal 43 base pairs of the 
promoter are involved in overexpression. By site directed mutagenesis we describe that retinoid-
related orphan receptor alpha (RORα), Sp1 and E2F elements are involved in the promoter activity. 
We established for the first time that estrogen-related receptor alpha (ERRα) is a transcription factor 
involved in the higher activation of the human ACSL4 promoter in breast cancer cells. Furthermore, 
a combination of inhibitors of ACSL4 and ERRα produced a synergistic decrease in MDA-MB-231 
cell proliferation. We also demonstrated that ERα restoration in triple negative breast cancer 
cells downregulates ACSL4 expression. The results presented in this manuscript demonstrated 
transcriptional mechanism is involved in the different expression of ACSL4 in human breast cancer cell 
lines of different aggressiveness.
It has been demonstrated that Acyl-CoA synthetase 4 (ACSL4) enzyme expression is elevated in cancer cells, 
which promotes an aggressive phenotype associated with the dysregulated production of eicosanoids, particu-
larly in breast, colon, hepatocellular and prostate cancer1–8. Previous reports by our group describing the role of 
ACSL4 in the aggressiveness of breast cancer1–3 have shown high expression and mRNA levels of this enzyme in 
highly aggressive triple negative breast cancer (TNBC) cell lines, which lack estrogen receptor alpha (ERα) and 
progesterone receptor and do not overexpress human epidermal growth factor 2 receptor protein, as compared 
to ERα-expressing cells of lower aggressiveness. Moreover, reports by other authors have shown a correlation 
between ACSL4 expression and aggressiveness in TNBC tumors in patients5,9.
Our group has further established a causal role of ACSL4 expression in the transformation of a non-aggressive 
phenotype into a highly aggressive one in vitro and in vivo1,3. Regarding functional aspects, our group and others 
have established ACSL4 involvement in the mechanism underlying increased breast cancer cell proliferation, 
invasion and migration, in vitro and in vivo1,3,5,9.
Using RNA-seq and functional proteomics, we have reported that the single overexpression of ACSL4 in breast 
cancer cells of low aggressiveness regulates a broad spectrum of signaling pathways involved in both tumori-
genesis and resistance to conventional treatments2. ACSL4 regulates signal transduction pathways implicated in 
cancer, such as the mTOR pathway, and its overexpression has been shown to decrease ERα levels2. In addition, 
we have shown the participation of ACSL4 in tumor resistance to hormone therapy2 and chemotherapy through 
the action of ABC transporters, with its downregulation or inhibition in TNBC cells contributing to effective 
therapeutic approaches10. Worth pointing out, while these studies focused on analyzing downstream elements 
regulated by ACSL4, the cellular mechanisms regulating ACSL4 expression under physiological and pathological 
conditions remain mostly unknown.
In particular, although the role of ACSL4 mediating an aggressive phenotype in breast cancer is well accepted, 
the regulation mechanisms involved in its overexpression in TNBC have not been elucidated yet. In this scenario, 
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the current work analyzes the mechanisms underlying the differential regulation of ACSL4 in TNBC and 
ERα-positive breast cancer cells, which may allow to identify therapeutic targets and possible future drug com-
binations. Our studies have rendered a successful characterization of the human ACSL4 promoter and different 
mechanisms regulating its action in breast cancer cells. Moreover, we demonstrate that estrogen-related receptor 
alpha (ERRα) is involved in the transcriptional upregulation of the ACSL4 gene.
Results
Functional characterization of ACSL4 promoter in human breast cancer cell lines. The construc-
tion pNL1.1-1681 carrying a fragment of ~1.8 kb in length of the human ACSL4 promoter which contains also 
most of the exon 1 sequence (Fig. 1) was analyzed by transient transfection in breast cancer cell lines (Fig. 2). 
The functionality of the human ACSL4 promoter in the regulation of transcription was assessed by its ability to 
drive the expression of the NanoLuc luciferase gene. The promoter was active in MDA-MB-231, T47D, Hs578T 
and MCF-7 cell lines. Most interestingly, the magnitude of activity in ERα-positive cells was significantly lower 
Figure 1. Nucleotide sequence of the human ACSL4 promoter and a part of exon 1. Sequences from −1681 to 
−874 (green), −873 to +80 (blue), and +81 to +123 (red). Black arrows indicate the positions of 5′ seriated 
deletions. Red arrows indicate the positions of 3′ seriated deletions. Putative transcription factor binding sites 
are boxed.
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than in TNBC cells, about half in value (Fig. 2). This transcriptional ability of the ACSL4 promoter correlates with 
previous observations of differences between lines in ACSL4 expression1,9.
For further studies, we chose two widely used cell lines, MDA-MB-231 and MCF-7 cells, as models of TNBC 
and ERα-positive breast cancer cells, respectively. To measure the activity of potential cis-acting elements, a series 
of reporter constructs were generated with progressively larger deletions from the 5′ end of the promoter. The 
activity observed in all constructs was significantly higher in MDA-MB-231 than in MCF-7 cells (Fig. 3a). The 
results obtained show that the promoter construction carrying a deletion of the 5′ end from position −1681 to 
−873 (pNL1.1-873) increased promoter activity by 2.8 times in both cell lines, suggesting that this region contains 
a negative regulatory element (p < 0.001), while the next deletion to position −605 did not generate significant 
changes. A further deletion to position −218 produced an increase in promoter activity in both lines (p < 0.001), 
being the most active construction of the series (Fig. 3a). However, in this deletion, the increase in activity was 
different for each cell line in contrast to what was observed for the other constructions up to here. The increases 
in promoter activity were 1.8-fold in MDA-MB-231 and a 2.4-fold increase in MCF-7 cells. Therefore, in this case, 
the difference in promoter activity between lines was smaller, which suggests that between positions −605 and 
−218 there may be at least one regulatory element of transcription acting differentially between the two cell lines 
under study. A next deletion to position −31 drastically reduced transcriptional activity (p < 0.001), as the signal 
fell to values roughly 30% below those observed for the entire sequence (Fig. 3a). These findings suggest that the 
fragment between −218 and −31 contains elements that positively regulate the basal expression of the gene.
To continue with the functional characterization of the promoter we made progressive deletions of the 3′ end 
choosing the pNL1.1 −873 plasmid, more active than pNL1.1-1681. Results show that the deletion from position 
+123 to +80 reduced transcriptional activity by half in MDA-MB-231 (p < 0.001) but not in MCF-7, demonstrat-
ing that this sequence fragment is relevant to activate the transcription of the ACSL4 gene only in MDA-MB-231 
(Fig. 3b). A subsequent deletion to −14 position produced a great fall in transcriptional activity in both cell lines 
respect of pNL1.1 −873 (p < 0.001) (Fig. 3b).
To confirm the effect observed, we generated a plasmid containing the sequence from position −1681 to +80, 
which was compared to the pNL1.1-1681 construct in both cell lines. The results obtained were in agreement 
with those observed in deletions on the plasmid pNL1.1 −873. The deletion of 43 bp from the 3′ end also reduced 
transcriptional activity by 50% only in the MDA-MB-231 cell line (p < 0.001), while transcriptional activity in 
MCF-7 cells remained unaltered (Fig. 3c). These results confirm that the first 43 bp of the promoter are involved 
in the increase in ACSL4 expression in MDA-MB-231 cells.
Sequence analysis of the human ACSL4 promoter and site-directed mutation effects of 
selected cis-elements. We performed an in silico analysis of the human ACSL4 promoter sequence with 
MatInspector software (http://www.genomatix.com). The analysis revealed the absence of TATA box and the 
presence of GC-rich sequences near the transcription initiation site as previously described11. With respect to 
cis elements, the analysis revealed several putative transcription factor binding sites (Supplementary Table S1). 
Considering a cut-off index higher than 85% and bibliographic evidence of transcription factor functionality, we 
selected Retinoid-related orphan receptor alpha (RORα), Sp1, E2F, and ERRα elements as potential transcrip-
tional regulators of human ACSL4 promoter. The analysis revealed no consensus sites for ERα.
Site-directed mutagenesis of the selected elements was performed on the pNL1.1-1681 construct.
Figure 2. ACSL4 promoter activity in breast cancer cell lines. The ACSL4 human promoter sequence and part of 
exon 1, from positions −1681 to +123, was cloned into the pNL1.1 vector upstream of the Nanoluc Luciferase 
gene (Nluc). This construct was then transfected into MCF-7, T47D, MDA-MB-231 and Hs578T cell lines. 
Cells were allowed to recover for 48 h, and Nanoluc Luciferase activity was then determined by luminescence. 
Nanoluc luciferase activity was normalized to EGFP fluorescence counts measured in the same equipment and 
expressed as arbitrary units as described in Material and Methods. For comparison between lines, the promoter 
activity was relativized to the mean of the luminescence units of the empty pNL1.1 vector. Results are expressed 
as the mean of +/−SEM arbitrary units of at least three independent experiments. ***p < 0.001 vs MCF-7.
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RORα is a transcription factor involved in the regulation of lipid metabolism and was suggested as a potential 
tumor suppressor12. A consensus site for RORα was located between positions −1359 to −1326 whose mutation 
increased promoter activity in both cell lines, suggesting that this factor may act as a repressor (Fig. 4b,c). These 
results correlate with those observed in the deletion of the 5′ end, region in which the RORα site is present.
Two binding sites were also found on the promoter for transcription factor Sp1, which is involved in the 
formation of transcription initiation complexes in TATA-less promoters. One of these sites was located between 
positions −130 and −110 and another between sites −53 and −37. A mutation of the consensus sequence for Sp1 
extending between positions −130 and −110 reduced promoter activity in both cell lines, suggesting an activat-
ing role of Sp1 (Fig. 4b,c). This result coincides with the activity observed in the deletional analysis in both cell 
lines for the promoter fragment between −218 and −31 positions, suggesting that Sp1 could be a transcription 
factor potentially involved in the basal activity of the human ACSL4 promoter.
The E2F transcription factor family is involved in the regulation of cell cycle progression13. Although sev-
eral E2F consensus sites were found in the entire extension of the promoter, our studies focused on the three 
Figure 3. Functional characterization of the ACSL4 human promoter in MDA-MB-231 and MCF-7 cells. 
Several constructs of the ACSL4 promoter cloned upstream of Nluc were transfected into MDA-MB-231 and 
MCF-7 cells. Cells were allowed to recover for 48 h, and Nanoluc Luciferase activity was then determined 
by luminescence. For comparison between lines, the promoter activity was relativized to the mean of the 
luminescence units of the empty pNL1.1 vector. (a) Results of transfection of a series of plasmids containing 
5′ unidirectional deletions of the ACSL4 promoter (pNL1.1 −1681, −873, −605, −218, −31). Schematic 
structure of constructs is shown, and positions −31 and −218 of the ACSL4 promoter are indicated. (b) 
Results of transfection of another series of plasmids containing 3′ unidirectional deletions of a fragment of 
the ACSL4 promoter (pNL1.1 −873, −873; +80, −873; −14). Schematic structure of constructs is shown, and 
positions −14, +80 and +123 of the sequence are indicated. (c) Results of transfection of pNL1.1 −1681 or 
pNL1.1−1681; +80 plasmids. Schematic structure of constructs is shown, and positions +80 and +123 of the 
sequence are indicated. Results are expressed as the mean +/− SEM arbitrary units of at least three independent 
experiments. a ***p < 0.001 vs pNL1.1–1681 of MDA-MB-231 cells.
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consensus sites located near the 3′ end of the promoter between positions +14 to +35, +52 to +69 and +97 to 
+113, from now referred to as E2F.a, E2F.b and E2F.c, respectively. The mutation for E2F.c decreased promoter 
activity in both cell lines, thus indicating an activating role in both cell lines under study (Fig. 5b,c). The E2F.b 
site generated an increase in promoter activity in both cell lines, which hints at a repressive role for this con-
sensus site in the two study models (Fig. 5b,c). The mutant construct E2F.a site may have an activating effect in 
MDA-MB-231 but a repressive one in MCF-7 cells (Fig. 5b,c). However, these results do not correlate with the 
activity observed in the 3′ end deletional analysis of the promoter.
Most interestingly, bioinformatics analysis also showed that the human ACSL4 promoter sequence contains 
a site for the ERRα transcription factor. The finding of this consensus site between positions −317 and −293 
was of specially interest, as high expression of ERRα is associated with greater aggressiveness and is considered 
a negative phenotype in the prognosis of breast cancer14–16. The expression of ERRα is higher in MDA-MB-231 
cells compared to the MCF-7 cell line (Fig. 6a) in line with previous report15. The mutation performed on the 
consensus site for ERRα significantly reduced promoter activity by half in the MDA-MB-231 cell line but 
exerted no effects in MCF-7 cells (Fig. 4b,c). These results may indicate that ERRα acts as an activator only in 
the MDA-MB-231 cell line and coincide with the differential increment in signal between lines observed in the 
deletion from −605 to −218 position in the 5′ deletional analysis.
Analysis of the role of ERRα on ACSL4 expression. Chromatin inmmunoprecipitation (ChIP) assays 
were conducted to further analyze the association of ERRα to the ACSL4 promoter sequence. Cross-linked 
sheared chromatin from MDA-MB-231 or MCF-7 cells was immunoprecipitated with anti-ERRα or anti-mouse 
IgG and the DNA recovered was subjected to real-time PCR. A PCR product specific to the ACSL4 promoter 
was amplified from anti-ERRα immunoprecipitated DNA samples from MDA-MB-231 cells. In contrast, no sig-
nificant amplification was observed with DNA recovered from immunoprecipitation using control IgG in this 
cell line. We observed a very low amplification signal from anti-ERRα immunoprecipitated DNA samples from 
MCF-7 cells compared to results observed in MDA-MB-231. The signal observed was similar to the obtained 
from samples using IgG control. These data clearly show the specific association of ERRα to the ACSL4 promoter 
in MDA-MB-231 cells.
We next disrupted the expression of endogenous ERRα using small hairpin RNA (shRNA) in order to ana-
lyze the effect on ACSL4 expression in MCF-7 and MDA-MB-231 cells. The shRNA targeting ERRα knocked 
down the expression of the protein (Fig. 6c), which in turn resulted in inhibition of ACSL4 promoter activity 
(Fig. 6f), mRNA levels (Fig. 6e) and protein expression (Fig. 6d) when compared to mock-transfected cells in 
Figure 4. Analysis of Sp1, ERRα and RORα binding sites by site-directed mutagenesis on MDA-MB-231 and 
MCF-7 cells. Mutants were generated by site-directed mutagenesis of the Sp1 (pNL1.1–Sp1), ERRα (pNL1.1–
ERRα), and RORα (pNL1.1–RORα) binding sites present in the pNL1.1 −1681 construct of the human ACSL4 
promoter (a) and were transfected into MDA-MB-231 (b) and MCF-7 (c) cells. Cells were allowed to recover 
for 48 h, and Nanoluc Luciferase activity was then determined by luminescence. For comparison between lines, 
the promoter activity was relativized to the mean of the luminescence units of the empty pNL1.1 vector. Results 
are expressed as the mean +/− SEM arbitrary units of at least three independent experiments. **p < 0.01; 
***p < 0.001 vs pNL1.1–1681.
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MDA-MB-231 cell line. No significant differences were observed in MCF-7 cell line (Fig. 6d–f). These results 
demonstrate for the first time the role of ERRα as an activator of ACSL4 transcription in MDA-MB-231 cells.
To further explore the role of ERRα in MDA-MB-231 cells we used its well recognized inverse agonist XCT-
79014,15,17 and analyzed protein expression and promoter activity of the ACSL4 gene. Incubation with XCT-790 
produced inhibition in ACSL4 levels analyzed by Western blot and also in promoter activity (Fig. 6g,h).
On the basis of results obtained regarding the action of ERRα on ACSL4 transcriptional activity and hence its 
expression, we next evaluated the effect of a combination of ERRα and ACSL4 inhibitors on MDA-MB-231 cell 
proliferation by combining submaximal concentrations of XCT-790 and triacsin C as ACSL4 inhibitor18,19 and 
subsequently assessing BrdU incorporation. The combination of both drugs generated a significant inhibition in 
cell proliferation, in contrast to single inhibitor treatment, which rendered no significant effects. These results 
demonstrate the synergistic inhibitory effect of the joint inhibitors of ERRα and ACSL4 (Fig. 6i).
Effect of restoring ERα expression in TNBC cells on ACSL4 expression. Previously, we have 
reported an inverse relationship between ACSL4 and ERα expression both in vitro and in vivo3. On the other 
hand, ERα silencing has been shown to enhance ACSL4 expression in MCF-75. However, our bioinformatics 
analysis of the cis-elements of the human ACSL4 promoter did not show consensus sequences for ERα. Therefore, 
to demonstrate that ERα regulates ACSL4 expression at transcriptional level, we restored the expression of this 
transcription factor in TNBC cells to analyze its effect on ACSL4 promoter activity, transcription and expres-
sion. We cotransfected the plasmid pSG5-ERα20 or its corresponding empty plasmid pSG5 into TNBC cell lines 
MDA-MB-231 (Fig. 7a) and Hs578T (Fig. 7b), with different constructions of ACSL4 promoter. Results showed 
ERα expression to reduce the activity of all constructions of the ACSL4 promoter tested (Fig. 7a,b). In turn, over-
expression of ERα in MDA-MB-231 decreased both the expression (Fig. 7c) and mRNA level of ACSL4 (Fig. 7d), 
as revealed by Western blot and qPCR assays, in agreement with the results obtained in promoter activity.
ChIP assays were conducted on ERα positive MCF-7 cell line to further analyze the association of ERα to the 
ACSL4 promoter sequence (Fig. 7e). Cross-linked sheared chromatin from MCF-7 cells was immunoprecipitated 
with anti-ERα or anti-mouse IgG and the DNA recovered was subjected to real-time PCR. We observed a very 
low amplification signal from anti-ERα immunoprecipitated DNA samples. The signal observed was similar to 
the obtained from samples using IgG control. These data do not support the association of ERα to the ACSL4 pro-
moter sequence (Fig. 7e). Following the analysis, we studied the effect of restoring ERα on ERRα protein levels 
in MDA-MB-231 cells. We observed that the expression of ERα produces a decrease in the expression levels of 
ERRα (Fig. 7g). Then we analyze the effect of ERα on the promoter activity containing the site directed mutation 
Figure 5. Analysis of E2F binding sites by site-directed mutagenesis on MDA-MB-231 and MCF-7 cells. 
Mutants were generated by site-directed mutagenesis of the E2F.a (pNL1.1–E2F.a), E2F.b (pNL1.1–E2F.b) and 
E2F.c (pNL1.1–E2F.c) binding sites present in the pNL1.1 −1681 construct of the human ACSL4 promoter (a) 
and were transfected into MDA-MB-231 (b) and MCF-7 (c) cells. Cells were allowed to recover for 48 h, and 
Nanoluc Luciferase activity was then determined by luminescence. For comparison between lines, the promoter 
activity was relativized to the mean of the luminescence units of the empty pNL1.1 vector. Results are expressed 
as the mean +/− SEM arbitrary units of at least three independent experiments. **p < 0.01; ***p < 0.001 vs 
pNL1.1–1681.
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Figure 6. Effect of ERRα on ACSL4 expression in breast cancer cells. (a) ERRα expression was analyzed by 
Western blot. (b) ChIP assay was performed from MDA-MB-231 or MCF-7 samples and immunoprecipitated 
with anti-ERRα antibody or normal mouse IgG as negative control. DNA was recovered and subjected to 
qPCR analysis using specific primers for the ACSL4 promoter region. qPCR results are expressed as % of input 
signal. a ***p < 0.001 vs negative controls, b ***p < 0.001 vs MCF-7. (c) MDA-MB-231 or MCF-7 cells were 
transiently transfected with the plasmid containing shRNA-ERRα (sh-ERRα) or the empty plasmid (Mock). 
(d) Then ACSL4 was evaluated by Western blot and (e) mRNA levels by qPCR. (f) pNL1.1–1681 construct was 
co-transfected either with shRNA-ERRα or empty plasmid (mock) into MDA-MB-231 or MCF-7 cells. Nanoluc 
luciferase activity was determined by luminescence. Results are expressed as the mean +/− SEM arbitrary units 
of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs Mock. (g) MDA-MB-231 cells 
were cultured in steroid-free medium and treated with 10 μM XCT-790 or DMSO as vehicle for 24 h. ACSL4 
expression was analyzed by Western blot. **p < 0.01 vs DMSO. (h) MDA-MB-231 cells cultured in steroid-free 
medium were transfected with the pNL1.1-1681 construct and treated with 10 μM XCT-790 or DMSO for 24 h. 
The activity of NanoLuc Luciferase was then determined by luminescence. The promoter activity was relativized 
to the mean of the luminescence units of the empty pNL1.1 vector. Results are expressed as the mean +/− SEM 
arbitrary units of at least three independent experiments. ***p < 0.001 vs DMSO. (i) MDA-MB-231 cells were 
plated at a density of 1200 cells/well in 96-well plates with complete D-MEM and incubated overnight. The 
medium was then changed to serum-free medium. After 24 h, the cells were switched to 10% FBS-supplemented 
D-MEM medium with triacsin C (0,5 μM) and/or XCT-790 (5 μM) for 96 h. DMSO was used as vehicle. 
Subsequently, cell proliferation was measured by BrdU incorporation assays. Results are expressed as the mean 
+/− SEM arbitrary units of at least three independent experiments. ***p < 0.001 vs single inhibitors.
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for ERRα. We observed that ERα expression produces a decrease in the activity of the construction that contains 
a mutation of the ERRα site, though slighter than the decrease observed in the wild type sequence (Fig. 7f).
Discussion
Here we demonstrate for the first time that differential transcriptional activity is involved in the regulation of 
ACSL4 expression in breast cancer cell lines. We cloned and functionally characterized the human ACSL4 pro-
moter in breast cancer cell lines and was functional in all the lines studied, exhibiting greater activity in TNBC 
cells. Both differences and common features were found in ACSL4 promoter regulation of the systems under 
study. Within the similarities observed, deletional analysis revealed that the sequence between −1681 and −873 
positions contains at least one negative regulator. Within this area a consensus site was found for RORα, which in 
normal cells is involved in the regulation of functions such as lipid metabolism21. Several actions for RORα have 
also been found in melanoma and breast cancer22,23, and the presence of RORα mRNA has been reported both in 
TNBC and ER-positive human breast cancer cells24. Through site-directed mutagenesis, we show that RORα may 
Figure 7. Effect of ERα expression restoration on ACSL4 expression and promoter activity. Three different 
constructs of the ACSL4 promoter (pNL1.1 −1681, pNL1.1 −873; +80 and pNL1.1 −873) were co-transfected 
either with the pSG5-ERα (ERα) expression plasmid or pSG5 (Mock) empty plasmid into MDA-MB-231 
cells (a) or Hs578T (b) cells. Cells were allowed to recover for 48 h, and Nanoluc luciferase activity was then 
determined by luminescence. For the analysis of ACSL4 expression and mRNA levels, MDA-MB-231 cells 
were transiently transfected either with ERα expression plasmid (ERα) or empty vector (Mock) and allowed 
to recover for 48 h. (c) ERα and ACSL4 expression was then analyzed by Western blot. ACSL4 signal was 
quantified by densitometry. Integrated optical density of ACSL4 was normalized against β-tubulin expression. 
(d) Total RNA was extracted, reverse-transcribed and ACSL4 and L19 human ribosomal protein (L19) mRNAs 
were subjected to real-time PCR. ACSL4 mRNA levels were normalized against the corresponding L19 mRNA 
levels. Results are expressed as the mean +/− SEM arbitrary units of at least three independent experiments. 
**p < 0.01vs Mock. (e) ChIP assay was performed using cross-linked sheared chromatin obtained from MCF-7 
and immunoprecipitated with anti-ERα antibody. Immunoprecipitation with normal mouse IgG was run as 
negative control. DNA was recovered and subjected to qPCR analysis using specific primers for the ACSL4 
promoter region. qPCR results are expressed as % of input signal. (f) The constructs pNL1.1–1681or pNL1.1–
ERRα were co-transfected either with the pSG5-ERα (ERα) expression plasmid or pSG5 (Mock) empty 
plasmid into MDA-MB-231 cells. Cells were allowed to recover for 48 h, and Nanoluc luciferase activity was 
then determined by luminescence. Results are expressed as the mean +/− SEM arbitrary units of at least three 
independent experiments. *p < 0.05,***p < 0.001 vs Mock. (g) ERRα expression was analyzed by Western blot 
in MDA-MB-231 transfected with the pSG5-ERα (ERα) expression plasmid or pSG5 (Mock) empty plasmid. 
Integrated optical density of ERRα was normalized against GAPDH expression. Results are expressed as the 
mean +/− SEM arbitrary units of at least three independent experiments. *p < 0.05 vs Mock.
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act as a negative regulator of the ACSL4 promoter. Given that lower expression of ACSL4 has been associated with 
lower aggressiveness in breast cancer1,3, the negative regulation of the ACSL4 promoter by RORα observed here 
is in line with the potential role of this transcription factor as a tumor suppressor12.
Adding up to the similarities observed, the sequence between −218 and −31 was found to be a positive regu-
latory zone. This result confirms that this fragment is responsible for most of the activity of the human promoter 
and might contain the necessary elements for basal transcription. The first 230 bp of the ACSL4 promoter are 
highly conserved (85% homology) between human and mouse species11, and consensus sites for Sp1 have been 
described in this region11,25. However, until now, no experimental data were available on the functionality of 
these elements in the human ACSL4 promoter. Sp1 is of particular interest, as it has been described as a CG bind-
ing transcription activator participating in the formation of transcription initiation complexes26. Site-directed 
mutagenesis of the Sp1 consensus sequence located between −130 and −110 positions indicated that it functions 
as an activator.
Most interestingly, we discovered differences in promoter functionality which were involved in the increase 
in ACSL4 transcriptional activity in MDA-MB-231 cells. In the current work, the 3′ deletional analysis demon-
strated that the 43 bp of the 3′ end of the ACSL4 promoter are relevant to the higher promoter activity, as the 
deletion of these bases surprisingly generated a fall which drove it to the same levels of MCF-7 cells. E2F.c consen-
sus site was located in this region. However, the analysis of E2F.c element indicates that it acts as an activator in 
both lines, which suggests that may not itself be involved in the differential activity observed in the 3′ end of the 
promoter. As possible explanations for the differential activity of the proximal 43 bp of the promoter, the deleted 
fragment may have eliminated alternative transcription starting sites, or different epigenetic modifications on 
the promoter of each cell line might influence the transcriptional activity; in both cases, the fall in the deletional 
analysis may not only be associated with the activity of consensus sites themselves.
Also as part of the 3′ deletional analysis, a deletion between −14 and +80 positions of the promoter was 
found to cause a greater fall in activity in both lines under study. Two additional consensus sequences for the E2F 
family were found in this region. Site-directed mutations of these cis-elements indicate that E2F.b may act as a 
repressor in both cell lines, while E2F.a might act as an activator in MDA-MB-231 and as a repressor in MCF-7. 
This difference found could be due to the fact that, in general, several members of the E2F family join a region of a 
promoter and that binding specificity of a particular factor may depend on the amount present of each member of 
the family in the nucleus27 or on the specific activity of a E2F family member in each cellular context28. However, 
as these results fail to completely support the difference in activity fall observed upon deletion of this fragment, 
the net effect of E2F may be thought to depend on the balance and interaction between activators and repressors 
of the E2F family in each cell type.
Most interestingly, results obtained in the 5′ deletional analysis suggest a difference between lines within the 
−605 and −218 positions. This difference may be explained by an activator probably acting only in MDA-MB-231 
cells in this zone. This fragment contains a consensus sequence for ERRα, a transcription factor identified on 
the basis of its homology with ERα. To exert its action, ERRα requires specific interaction with coactivators or 
corepressors29,30. It has been reported that ERRα is differentially expressed in cancerous cells of different aggres-
siveness15. In correspondence with the expression of ACSL4 in breast cancer2,3,9, a negative correlation has been 
established between expression levels of ERα and ERRα in breast cancer tumor samples31. ERRα is considered 
a negative prognostic marker for the disease, as its expression in breast carcinoma has been associated with 
increased risk of recurrence and adverse clinical progression32. Moreover, ERRα is known to induce the expres-
sion of vascular endothelial growth factor in different breast cancer cell lines33, and to increase metastatic capacity 
in breast tumors15,34. It has been shown in vitro and in vivo that ERRα is involved in the epithelial-mesenchymal 
transition15. Like the ACSL4 functions reported in relation to aggressiveness in breast cancer cell lines1,3,5, ERRα 
expression promotes cellular migration, invasion and tumor growth15. All this evidence justified our study of 
ERRα cis-element in the ACSL4 promoter. Site-directed mutagenesis results indicated that ERRα acts as an 
activator only in MDA-MB-231 cells, which correlates with the deletional analysis of the zone. ERRα binding 
to the ACSL4 promoter was confirmed through ChIP assays in MDA-MB-231 cells. In line with these results, 
inhibition of ERRα expression by shRNA resulted in decreased ACSL4 promoter activity, mRNA and protein 
levels only en MDA-MB-231 cells. This result demonstrates that ERRα regulates ACSL4 at transcriptional level. 
Furthermore, we evaluated ERRα role in the regulation of ACSL4 using the specific ERRα inverse agonist XCT-
790 and observed that both the activity of the promoter and the expression of ACSL4 decrease significantly upon 
ERRα inhibition in MDA-MB-231 cells. Altogether, these findings demonstrate for the first time that ERRα is a 
transcription factor involved in the upregulation of the expression of ACSL4 in MDA-MB-231 cells. In addition, 
the current work shows that inhibitors of ACSL4 and ERRα reduces the proliferation of MDA-MB-231 cells in a 
synergistic way. A previous work showed an uncoupling effect of XCT-790 independent of ERRα35. We cannot 
rule out that this effect also could be participating in the observed results.
Additionally, we observed a relationship between ERRα activity and the 43 bp function of the 3′ end of the 
promoter. Both pNL1.1 −1681; +80 and pNL1.1 −873; +80 contain the consensus site for ERRα; however, the 
activity of these constructs lacking the 43 bp of the 3′ end did not show significant differences between cell lines, 
which indicates that ERRα stimulatory effect on the ACSL4 promoter in MDA-MB-231 may not be maintained 
when the 43 bp of the 3′ end are deleted. At the same time, it is worth pointing out the need of ERRα binding to 
maintain the difference between cell lines, given that the mutant construction for ERRα on the whole promoter 
caused a fall in transcriptional activity in MDA-MB-231 to levels similar to those of MCF-7 cells. This evidence 
suggests that both the 43 bp of the 3′ end of the promoter and ERRα action might be necessary to produce differ-
ential regulation between cell lines of different aggressiveness.
We also evaluated the role of ERα in the regulation of ACSL4. Previous reports have established an inverse 
relationship between the expression of ACSL4 and ERα in breast cancer, as shown both in cancer cell lines and 
patients’ breast tumors, and indicate that ACSL4 negatively modulates the expression of ERα3,5,9. Furthermore, 
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the silencing of ACSL4 in MDA-MB-231 cells restores ERα expression2, which is in line with results obtained 
by other authors through the overexpression of ACSL4 in MCF-7 cells5. Moreover, the regulation of ERα by 
ACSL4 seems to be reciprocal, as ERα silencing in MCF-7 cells induces ACSL4 expression, which indicates that 
ERα in turn modulates the expression of ACSL45. However, the effects of ERα restoration on TNBC cells had 
not been evaluated before. Our current results upon restoring ERα expression in TNBC cells show a decrease in 
ACSL4 promoter activity. Furthermore, in MDA-MB-231 cells, we demonstrate that the effects observed on the 
promoter are consequently reflected in a decrease in ACSL4 protein and mRNA levels. In this way, we confirm 
that this transcription factor negatively regulates ACSL4 expression. As bioinformatic analysis of cis-elements on 
the human ACSL4 promoter revealed no consensus sequences for ERα. In our ChIP experiments we could not 
detect a significant binding of ERα to the ACSL4 promoter. We hypothesize that this transcription factor may be 
thought to regulate the ACSL4 promoter by an indirect regulatory mechanism. We observed that the restoration 
of ERα expression produces a decrease in ERRα protein in MDA-MB-231 cells. We showed that the effect of 
ERα on the promoter activity persists even when the consensus site of ERRα is mutated, though slighter than 
the decrease observed in the wild type sequence. We conclude that binding to the promoter sequence may not 
play a key role in the effect of ERα on the expression of ACSL4, and this effect could be produced in part by the 
regulation it exerts on ERRα.
In conclusion, the results presented in this manuscript demonstrate that the different expression of ACSL4 in 
human breast cancer cell lines of different aggressiveness is at least partly due to a different transcriptional regu-
lation. We have established for the first time that ERRα is a transcription factor involved in the higher activation 
of the human ACSL4 promoter in TNBC cell lines. Previous studies have proposed ERRα as a possible therapeu-
tic target in breast cancer and its inhibition is currently under study as a new strategy for TNBC treatment14,15. 
Therefore, the future joint study of ACSL4 and ERRα could lead to the design of new drug combinations for 
greater effectiveness in the treatment of highly aggressive breast cancer. Moreover, we show that ERα exerts 
a negative regulation on the expression of ACSL4 which might partially explain its overexpression in TNBC. 
Additional elements on the ACSL4 promoter with effects on gene transcription remain to be identified in further 
studies which will help to elucidate the molecular mechanisms underlying abnormal ACSL4 expression in patho-
logical conditions and potentially identify new pathways of regulation.
Methods
Materials. Dulbecco’s modified eagle medium (DMEM), Opti-MEM, Lipofectamine 2000, penicillin-strepto-
mycin solution, trypsin-EDTA and PCR primers were purchased from ThermoFisher Scientific (Waltham, MA, 
USA). Fetal bovine serum (FBS) was from PAA laboratories GmbH (Pasching, Austria). XCT-790 was from 
Sigma Chemical Co. (St. Louis, MO, USA). Triacsin C was from Enzo Life Sciences (Farmingdale, NY, USA). 
Polyclonal rabbit antibody anti-ACSL4 was generated in our laboratory36. Monoclonal mouse anti-GAPDH and 
polyclonal rabbit anti-ERα antibodies were from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Monoclonal 
mouse anti-β-tubulin was from Upstate Group Inc (Temecula, CA, USA). Polyclonal rabbit anti-ERRα chro-
matin immunoprecipitation (ChIP) grade was from Abcam (Cambridge, UK). Horseradish peroxidase-con-
jugated goat anti-rabbit and goat anti-mouse secondary antibodies and Immuno-Blot PDVF membrane were 
from Bio-Rad Laboratories (Hercules, CA, USA). Enhanced chemiluminescence (ECL) was from GE Healthcare 
(Buckinghamshire, UK). Sterile and plastic material for tissue culture was from Orange Scientific (Braine-
l′Alleud, Belgium). All other reagents were of the highest grade available.
Cell culture and treatments. Human breast cancer cell lines MDA-MB-231, Hs578-T, MCF-7 and T47D 
were generously provided by Dr. Vasilios Papadopoulos (School of Pharmacy, University of Southern California, 
Los Angeles, CA, USA) or obtained from the Lombardi Comprehensive Cancer Center (Georgetown University 
Medical Center, Washington D.C., USA). All cell lines were cultured in DMEM with glucose (4500 mg/l) supple-
mented with heat-inactivated FBS (10%) plus penicillin (100 U/ml) and streptomycin (10 μg/ml) and maintained 
in a 5% CO2 humidified atmosphere. The experiments for ERRα inhibition were performed in steroid free con-
dition as indicated in the literature14,15.
Promoter cloning and Nanoluc luciferase reporter construct generation. Genomic DNA was 
amplified with the specific primers (Table 1) containing XhoI and HindIII restriction sites. A ~1.8 kb sequence 
containing the ACSL4 human promoter was cloned into a pNL1.1 vector (Promega Corp., Madison, WI, USA) 
creating the plasmid pNL1.1-1681. An equal procedure was followed to obtain plasmids pNL1.1-873, −605, −218 
and −31, containing 5′ unidirectional deletions of the promoter or pNL1.1 −873; +80 and pNL1.1 −873;−14 
containing 3′ unidirectional deletions of the pNL1.1-873 construct, using the corresponding specific pairs of 
primers (Table 1). In the same way, the pNL1.1 −1681; +80 plasmid was obtained using the specific primers 
(Table 1). Reporter constructs pNL1.1–E2F.a, -E2F.b, -E2F.c, –RORα, –Sp1 and –ERRα consist of pNL1.1-1681 
carrying mutations in the corresponding putative transcription factor binding sites and were generated with Quik 
Change Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) following the suppliers’ 
instructions. All plasmids were fully sequenced for verification purposes (Macrogen, Korea).
For luciferase reporter assays, cells were plated in 48-well plates (100,000 cells/well). Transfection was per-
formed 24 h later with the different reporter plasmids, using Lipofectamine 2000. All reporter plasmids were 
used in equimolar amounts, and pBluescript DNA was used as needed to keep the total amount of DNA constant. 
Plasmid pRc/CMVi (Life Technologies, Carlsbad, CA, USA) expressing the EGFP gene was used for normal-
ization37. After transfection, total lysates were recovered using passive lysis buffer and luciferase activity was 
analyzed through the Nano-Glo® Luciferase Assay System (Promega), and luminescense was measured using an 
automated plate reader (Synergy HT, BioTek, Winooski, VT, USA). Nanoluc luciferase activity was normalized to 
EGFP fluorescence counts measured in the same equipment and expressed as arbitrary units.
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The plasmid sh-ERRα was generated by cloning the annealed primers 5′GATCCCCCTCGGAGACAGAG 
ACCGAGTTCAAGAGACTCGGTCTCTGTCTCCGAGTTTTTA 3′ and 5′ AGCTTAAAAACTCGGAGACAGA 
GACCGAGTCTCTTGAACTCGGTCTCTGTCTCCGAGGGG 3′ into pSUPER.retro.puro as previously described1. 
The plasmid PSG5-ERα20 was used for restoring ERα expression.
Chromatin immunoprecipitation (ChIP) assay. ChIP assays were performed following the manu-
facturer’s protocol of the EZ-ChIP assay kit (EMD Millipore Corporation, Billerica, MA, USA) as previously 
described11. Briefly, formaldehyde was added to cell cultures to a final concentration of 1% for 10 min at 37 °C. 
After the addition of glycine, cells were collected, pelleted and resuspended in the provided SDS-lysis buffer 
(6 × 106 cells/100 µl). For chromatine fragmentation, sonication was performed using a Branson Sonifier 250 
(VWR International, Radnor, PA, USA) for 6 cycles of 10 s pulses with an amplitude of 10%. Chromatin frag-
ments were determined to be between 200–1000 bp in size. Sheared chromatin was immunoprecipitated over-
night with anti-ERRα antibody. Immunoprecipitation with normal mouse IgG or absence of antibody were run 
as negative controls. Immunocomplexes were collected using salmon sperm/protein A-agarose slurry and sub-
sequently washed and eluted using SDS containing elution buffer. Formaldehyde cross-links of samples, controls 
and input were reversed and DNA was purified. Real time PCR was performed using promoter-specific primers 
(Table 1). The bound DNA was calculated in equation 1 as % input using the Ct values as previously described38. 




Ct[adjusted ChIP] Ct[ChIP] (Ct[Input]
Log (Input Dilution Factor))
% Input 100/2 (1)
2
Ct[adjusted ChIP]
RNA extraction and real-time PCR. For quantitative real-time PCR total RNA was extracted using Tri 
Reagent following the manufacturer’s instructions (Molecular Research Center Inc., Cincinnati, OH, USA). 
Isolated RNA was deoxyribonuclease-treated using RNAse-free DNase RQ1 (Promega). Reverse transcription 
was done using total RNA (2 μg) and M-MLV Reverse Transcriptase (Promega). Reactions were carried out using 
the SYBR Green Master Mix reagent kit (Applied Biosystems, Carlsbad, CA, USA) and using the specific primers 
for qPCR (Table 1). The reaction conditions were: one 5 min cycle at 95 °C, followed by 40 cycles at 95 °C for 15 s, 
60 °C for 30 s, and 72 °C for 30 s. Gene mRNA expression levels were normalized to human L19 RNA expression, 
performed in parallel as endogenous control. Real-time PCR data were analyzed by calculating the 2−ΔΔCt 
value (comparative Ct method) for each experimental sample.
Reaction Primer Primer sequence (5′-3′)
Promoter cloning
ACSL4 promoter forward AAA CTC GAG TGG GCT AAG AGA CCG ACA ATA
ACSL4 promoter reverse TTT AAG CTT GGC ACT CGG AAA GCT CGC AAA
5′ deletions
del −31 AAA CTC GAG GCG TCT TTT CCG GGC TCG
del −218 AAA CTC GAG GTT AGC CGC CTC GCC TTC
del −605 AAA CTC GAG ACG TGA AAA TCC TGC GTC CTT
del −873 AAA CTC GAG GAA TTC TTG AGA TTT ATT TTT TTG G
3′ deletions
del + 80 TTT AAG CTT CGC TGG GAC GAG GAG GA
del −14 TTT AAG CTT GAG CCC GGA AAA GAC GC
Site-directed mutagenesis
E2F.a forward GTC CGG GTG CGC AAG CGC CGC TGC GGC
E2F.a reverse GCC GCA GCG GCG CTT GCG CAC CCG GAC
E2F.b forward GGC CTC CGC CGC GAA CTC CTC CTC GTC C
E2F.b reverse GGA CGA GGA GGA GTT CGC GGC GGA GGC C
E2F.c forward GCA CGC GGT TCC TTC TTG CGA GCT TTC CG
E2F.c reverse CGG AAA GCT CGC AAG AAG GAA CCG CGT GC
Sp1 forward CGG GCG AGC GGG TGC GGG CGC GTG G
Sp1 reverse CCA CGC GCC CGC ACC CGC TCG CCC G
ERRα forward CTG CTG TTA GGC GCA AGG CTA TCC CGA AAC ACA CTC AAC
ERRα reverse GTT GAG TGT GTT TCG GGA TAG CCT TGC GCC TAA CAG CAG
RORα forward GAA GTA CTG AAC TTT GTT GGT CAA TCT TGA AAA AG
RORα reverse CTT TTT CAA GAT TGA CCA ACA AAG TTC AGT ACT TC
qPCR
ACSL4 forward CCC GCT ATC TCC TCA GAC AC
ACSL4 reverse CAA TTT CAT GGC ATT TGC AG
L19 forward AGT ATG CTC AGG CTT CAG AA
L19 reverse TTC CTT GGT CTT AGA CCT GC
ChIP
ERRα ChIP forward GTG GAG TCC TGC GAA GCA AG
ERRα ChIP reverse CGG CTC CGC CTC AAG TTG TTG
Table 1. Primers used in the expression and functional analysis of the ACSL4 promoter.
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Western blot. Western blot was performed as previously described36. Appropriate dilutions of primary anti-
bodies were used as recommended by the manufacturer. The polyclonal rabbit antibody anti-ACSL4 generated in 
our laboratory was used in a dilution of 1:100036.
Cell proliferation assays. Cell proliferation was measured by 5-bromo-2′-deoxyuridine (BrdU) incorpora-
tion using BrdU cell proliferation ELISA kit (Roche Diagnostics, Basel, Switzerland) following the manufacturer’s 
instructions as previously described2.
Sequence and statistical analysis. Sequence analysis was performed with Vector NTi (Informax, 
Invitrogen, Carlsbad, CA, USA). Identification of putative transcription factor binding sites was achieved using 
MatInspector version 2.2 (Genomatix, Inc., Munich, Germany). Statistical analyses were performed with PRISM 
version 3.0 (GraphPad, Inc., La Jolla, CA, USA).
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